Original Research Article
Year: 2021 | Month: March | Volume: 8 | Issue: 3 | Pages: 321-325
An Observational Study to Evaluate Effect of Vildagliptin in Combination with Metformin and Glimepiride on Glycaemic Control and lipid profile in T2DM Patients
Dipti Ranjan Darjee
Asst. Professor, Dept. of Medicine, SCB Medical College, Cuttack
ABSTRACT
Objective: The study was conducted to evaluate the effect of addition of Vildagliptin in patients on glycaemic control (Plasma glucose and HbA1c) and Lipid Profile [Triglyceride (TG), Total cholesterol (TC), Low density lipoprotein cholesterol (LDL-C), High density lipoprotein cholesterol (HDL-C)] who were inadequately control with glimepiride and metformin therapy.
Material and Method: This was a prospective observational study and patients who were not adequately control with metformin and glimepiride were included in this study. Patients who were having HbA1c > 8% and comparably higher lipid profile were included in this study. All serological test were performed from NABL accelerated pathological laboratory. Efficacy were measured by the changes in glycemic parameters and in lipid profile from baseline to 12 weeks.
Result: At the end of 12 weeks there were statistical significant drop in glycemic parameters i.e., fasting plasma glucose (p<0.05), post prandial plasma glucose (p<0.05) and glycated haemoglobin (HbA1c%) (p<0.05). There also a significant change observed in lipid profile but there was not significant increase in High density lipoprotein cholesterol (HDL-C). Hypoglycaemic events was significantly low as compare to baseline.
Conclusion: Addition of Vildagliptin in uncontrolled T2DM patients will significantly bring down the glycemic level. Patients who were uncontrolled with metformin and glimepiride therapy will be benefited in both in terms go glycemic control and lipid control after addition of DPP4i like Vildagliptin.
Keywords: Vildagliptin, glimepiride, metformin, T2DM.
[PDF Full Text]